Compare CSX Corporation (CSX) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Citius Pharmaceuticals Inc — how do they compare? CSX Corporation trades at $47.26 (market cap $87.70B), while Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M). The key difference: CSX Corporation is far larger — about 6439.1× Citius Pharmaceuticals Inc's market cap, and CSX Corporation pays a 1.18% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Citius Pharmaceuticals Inc for 17 Days on average.
| CSX | CTXR | |
|---|---|---|
Market Cap | $87.70B | $13.62M |
Volume | 6,980,781 | 132,438 |
Sector | Industrials | Health |
52-Week High | $53.21 | $1.82 |
52-Week Low | $33.68 | $0.48 |
Typical Hold Time | 55 Days | 17 Days |
Enterprise Value | $105.66B | $3.79M |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, up 1.13% today, with a bullish technical signal and strong institutional interest. Recent earnings show a beat in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, with net income falling to $2.89B. The company maintains solid profitability with a 22.21% net margin and 24.37% ROE, but valuation ratios like P/E of 27.52 and P/S of 6.08 appear elevated. A dividend of $0.14 is scheduled for payment in September 2026.
The outlook for CSX is cautiously optimistic, supported by analyst consensus with a $51 price target and 58.69% buy ratings. Key opportunities include pricing power in freight rail and expected earnings recovery in 2026. Risks involve revenue declines, high debt levels, and sensitivity to economic cycles. The stock's current technical strength and institutional accumulation suggest potential upside if operational trends improve.
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
